Leap therapeutics publishes the latest data of dkn-01 single drug treatment and paclitaxel combination treatment

Leap therapeutics, Inc today announced the clinical phase II results of its product dkn-01, which will be presented at the International Association of gynecological cancer annual global conference 2019, to be held in Rio de Janeiro from September 19 to 21, 2019 Results the results will be presented in two forms: oral report and poster report, including the results of the second phase clinical study of dkn-01 as a single therapy and combined with paclitaxel chemotherapy "We are very keen to observe the activity of dkn-01 single drug and combination drug in this group of pre-treatment patients Dkn-01 targets DKK1, a regulator of Wnt cell pathway In this study, dkn-01 showed a clinical response to the drug in patients with Wnt activated mutations and high levels of DKK1, and achieved a prolonged progression free survival (PFS) in treated patients " Dr Rebecca C Arend, M.D., gynecology and obstetrics, Birmingham School of medicine, University of Alabama, commented that he would present part of the data on behalf of the research team: "the complete response of single drug treatment and the correlation between patient results and major tumor biomarkers are impressive results of patient progress These patients have poor prognosis and few treatment options " The main findings of P204 study include: 1 Complete response to dkn-01 single drug treatment; 2 Patients with Wnt activated mutation have longer PFS; 3 Patients with DKK1 overexpression have longer PFS; 4 The survival rate of patients with Wnt activated mutation or DKK1 overexpression is very low (BIOON Com) original source: leap therapeutics official website